litlas
ログインアカウント作成

Stephen J. Schuster

1993–2026 年に発表

別表記
Stephen J Schuster
180
論文数
29,799
被引用数
77
h 指数
166
i10 指数

被引用数

Stephen J. Schuster の年別被引用数1992 年: 被引用 1 件1993 年: 被引用 2 件1994 年: 被引用 2 件1999 年: 被引用 2 件2000 年: 被引用 1 件2001 年: 被引用 5 件2002 年: 被引用 4 件2003 年: 被引用 10 件2004 年: 被引用 24 件2005 年: 被引用 39 件2006 年: 被引用 44 件2007 年: 被引用 42 件2008 年: 被引用 32 件2009 年: 被引用 30 件2010 年: 被引用 52 件2011 年: 被引用 52 件2012 年: 被引用 36 件2013 年: 被引用 51 件2014 年: 被引用 55 件2015 年: 被引用 227 件2016 年: 被引用 247 件2017 年: 被引用 329 件2018 年: 被引用 356 件2019 年: 被引用 1,070 件2020 年: 被引用 1,505 件2021 年: 被引用 1,485 件2022 年: 被引用 1,390 件2023 年: 被引用 1,232 件2024 年: 被引用 2,110 件2025 年: 被引用 1,096 件2026 年: 被引用 32 件1995〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,126 件、この内訳の 30.4%中国: 引用元論文 1,371 件、この内訳の 10.1%ドイツ: 引用元論文 870 件、この内訳の 6.4%イギリス: 引用元論文 743 件、この内訳の 5.5%イタリア: 引用元論文 680 件、この内訳の 5%フランス: 引用元論文 643 件、この内訳の 4.7%スペイン: 引用元論文 487 件、この内訳の 3.6%カナダ: 引用元論文 415 件、この内訳の 3.1%オーストラリア: 引用元論文 403 件、この内訳の 3%スイス: 引用元論文 375 件、この内訳の 2.8%日本: 引用元論文 317 件、この内訳の 2.3%オランダ: 引用元論文 317 件、この内訳の 2.3%
0%30.4%その他 20.8%

機関

分野

  • Medicine86.3%
  • Biochemistry, Genetics and Molecular Biology6.9%
  • Immunology and Microbiology5.5%
  • Engineering0.4%
  • Neuroscience0.1%
  • Chemistry0.1%
  • その他0.7%

トピック

  • CAR-T cell therapy research18%
  • Lymphoma Diagnosis and Treatment9.4%
  • Cancer Immunotherapy and Biomarkers6.4%
  • Chronic Lymphocytic Leukemia Research5.6%
  • Immune Cell Function and Interaction5.2%
  • Virus-based gene therapy research3.7%
  • その他51.7%

共著者

全論文

検索で開く
  1. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    著者: Stephen J. Schuster, Michael Bishop, Constantine S. Tam, Edmund K. Waller, Peter Borchmann, Joseph P. McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R. Westin, Isabelle Fleury, Veronika Bachanová, S.R. Foley, P. Joy Ho, Stephan Mielke, John Magenau, Harald Holte, Serafino Pantano, Lida Pacaud, Rakesh Awasthi, Jufen Chu, Özlem Anak, Gilles Salles, Richard T. Maziarz - New England Journal of Medicine 2018 被引用: 4,044

  2. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

    著者: Stephen J. Schuster, Jakub Svoboda, Elise A. Chong, Sunita D. Nasta, Anthony R. Mato, Özlem Anak, Jennifer L. Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj, Daniel J. Landsburg, Mariusz A. Wasik, Bruce L. Levine, Simon F. Lacey, J. Joseph Melenhorst, David L. Porter, Carl H. June - New England Journal of Medicine 2017 被引用: 1,854

  3. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

    著者: Nathan Fowler, Michael Dickinson, Martin Dreyling, Joaquín Martínez‐López, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chávez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, José Antonio Pérez‐Simón, Andy I. Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés J.M. Ferreri, Takanori Teshima, Piers Patten, Joseph P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thiéblemont - Nature Medicine 2021 被引用: 527

  4. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

    著者: Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Chan Y. Cheah, Michael C. Wei, Shen Yin, Chi‐Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Nancy L. Bartlett - The Lancet Oncology 2022 被引用: 436

  5. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

    著者: Stephen J. Schuster, Constantine S. Tam, Peter Borchmann, Nina Worel, Joseph P. McGuirk, Harald Holte, Edmund K. Waller, Samantha Jaglowski, Michael Bishop, Lloyd E. Damon, S.R. Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Murali Janakiram, Jing-Mei Hsu, Koji Izutsu, Marie José Kersten, Monalisa Ghosh, Nina D. Wagner‐Johnston, Koji Kato, Paolo Corradini, Marcela Martínez-Prieto, Xia Han, Ranjan Tiwari, Gilles Salles, Richard T. Maziarz - The Lancet Oncology 2021 被引用: 561

  6. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

    著者: Guido Ghilardi, Joseph A. Fraietta, James N. Gerson, Vivianna M. Van Deerlin, Jennifer J.D. Morrissette, Gabriel C. Caponetti, Luca Paruzzo, Jaryse Harris, Elise A. Chong, Sandra P. Susanibar-Adaniya, Jakub Svoboda, Sunita D. Nasta, Ositadimma Ugwuanyi, Daniel J. Landsburg, Eugenio Fardella, Adam Waxman, Emeline R. Chong, Vrutti Patel, Raymone Pajarillo, Irina Kulikovskaya, David Lieberman, Adam D. Cohen, Bruce L. Levine, Edward A. Stadtmauer, Noelle V. Frey, Dan T. Vogl, Elizabeth O. Hexner, Stefan K. Barta, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Carl H. June, Marco Ruella - Nature Medicine 2024 被引用: 256

  7. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    著者: Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C. Scott, Martin Gutierrez, Stephen J. Schuster, Michael Millenson, Deepika Cattry, Gordon J. Freeman, Scott J. Rodig, Bjoern Chapuy, Azra H. Ligon, Lili Zhu, Joseph F. Grosso, Su Young Kim, John M. Timmerman, Margaret A. Shipp, Philippe Armand - New England Journal of Medicine 2014 被引用: 3,547

  8. An NK-like CAR T cell transition in CAR T cell dysfunction

    著者: Charly R. Good, M. Ángela Aznar, Shunichiro Kuramitsu, Parisa Samareh, Sangya Agarwal, Greg Donahue, Kenichi Ishiyama, Nils Wellhausen, Austin K. Rennels, Yujie Ma, Lifeng Tian, Sònia Guedan, Katherine A. Alexander, Zhen Zhang, Philipp C. Rommel, Nathan Singh, Karl M. Glastad, Max W. Richardson, Keisuke Watanabe, János L. Tanyi, Mark H. O’Hara, Marco Ruella, Simon F. Lacey, Edmund K. Moon, Stephen J. Schuster, Steven Μ. Albelda, Lewis L. Lanier, Regina M. Young, Shelley L. Berger, Carl H. June - Cell 2021 被引用: 417

  9. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    著者: Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian W. Flinn, Werner Rabitsch, Yok‐Lam Kwong, Marie José Kersten, Monique C. Minnema, Harald Holte, Esther Hian Li Chan, Joaquín Martínez‐López, Antonia Müller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David A. Bond, Charalambos Andreadis, Peter A. McSweeney, Mohamed A. Kharfan‐Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jäger, Peter Borchmann, Jason R. Westin - New England Journal of Medicine 2021 被引用: 520

  10. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

    著者: Melody Smith, Anqi Dai, Guido Ghilardi, Kimberly V. Amelsberg, Sean M. Devlin, Raymone Pajarillo, John Slingerland, Silvia Beghi, Pamela S. Herrera, Paul A. Giardina, Annelie Clurman, Emmanuel Agyemang Dwomoh, Gabriel K. Armijo, Antonio L. C. Gomes, Eric R. Littmann, Jonas Schlüter, Emily Fontana, Ying Taur, Jae H. Park, Maria Lia Palomba, Elizabeth Halton, Josel D. Ruiz, Tania Jain, Martina Pennisi, Aishat Olaide Afuye, Miguel‐Angel Perales, Craig W. Freyer, Alfred L. Garfall, Shannon Gier, Sunita D. Nasta, Daniel J. Landsburg, James N. Gerson, Jakub Svoboda, Justin R. Cross, Elise A. Chong, Sergio Giralt, Saar Gill, Isabelle Rivière, David L. Porter, Stephen J. Schuster, Michel Sadelain, Noelle V. Frey, Renier J. Brentjens, Carl H. June, Eric G. Pamer, Jonathan U. Peled, Andrea Facciabene, Marcel R.M. van den Brink, Marco Ruella - Nature Medicine 2022 被引用: 309

  11. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

    著者: Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Carol O'Hear, Huang Huang, Antonia Kwan, Chi-Chung Li, Emily C. Piccione, Michael C. Wei, Shen Yin, Nancy L. Bartlett - Journal of Clinical Oncology 2021 被引用: 290

  12. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

    著者: Elise A. Chong, Marco Ruella, Stephen J. Schuster - New England Journal of Medicine 2021 被引用: 332

  13. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

    著者: Tanya Siddiqi, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob D. Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena Perna, Sherilyn A. Tuazon, San-San Ou, Eniko Papp, Leanne Peiser, Yizhe Chen, William G. Wierda - The Lancet 2023 被引用: 198

  14. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

    著者: Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Y. Cheah, John M. Pagel, Jennifer A. Woyach, Bita Fakhri, Toby A. Eyre, Nicole Lamanna, Manish R. Patel, Alvaro J. Alencar, Ewa Lech‐Marańda, William G. Wierda, Catherine C. Coombs, James N. Gerson, Paolo Ghia, Steven Le Gouill, David Lewis, Suchitra Sundaram, Jonathon B. Cohen, Ian W. Flinn, Constantine S. Tam, Minal Barve, Bryone J. Kuss, Justin Taylor, Omar Abdel‐Wahab, Stephen J. Schuster, M. Lia Palomba, Katharine L. Lewis, Lindsey E. Roeker, Matthew S. Davids, Xuan Tan, Timothy S. Fenske, Johan Wallin, Donald E. Tsai, Nora Ku, Edward Y. Zhu, Jessica Chen, Ming Yin, Binoj C. Nair, Kevin Ebata, Narasimha Marella, Jennifer R. Brown, Michael Wang - The Lancet 2021 被引用: 454

  15. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy

    著者: Elise A. Chong, Cécile Alanio, Jakub Svoboda, Sunita D. Nasta, Daniel J. Landsburg, Simon F. Lacey, Marco Ruella, Siddharth Bhattacharyya, E. John Wherry, Stephen J. Schuster - Blood 2021 被引用: 191

  16. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

    著者: John C. Byrd, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Neil E. Kay, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Steve Devereux, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Florence Cymbalista, Christopher Pocock, Patrick Thornton, Federico Caligaris‐Cappio, Tadeusz Robak, Julio Delgado, Stephen J. Schuster, Marco Montillo, Anna Schuh, Sven de Vos, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Jeffrey J. Jones, Alvina D. Chu, Maria Fardis, Jesse McGreivy, Fong Clow, Danelle F. James, Peter Hillmen - New England Journal of Medicine 2014 被引用: 1,617

  17. PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

    著者: Elise A. Chong, J. Joseph Melenhorst, Simon F. Lacey, David E Ambrose, Vanessa Gonzalez, Bruce L. Levine, Carl H. June, Stephen J. Schuster - Blood 2016 被引用: 497

  18. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

    著者: Vijay Bhoj, Dimitrios C. Arhontoulis, Gerald Wertheim, James Capobianchi, Colleen Callahan, Christoph T. Ellebrecht, Amrom E. Obstfeld, Simon F. Lacey, J. Joseph Melenhorst, Farzana Nazimuddin, Wei‐Ting Hwang, Shannon L. Maude, Mariusz A. Wasik, Adam Bagg, Stephen J. Schuster, Michael D. Feldman, David L. Porter, Stephen Grupp, Carl H. June, Michael C. Milone - Blood 2016 被引用: 271

  19. Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials

    著者: Jason R. Westin, Marie José Kersten, Gilles Salles, Jeremy S. Abramson, Stephen J. Schuster, Frederick L. Locke, Charalambos Andreadis - American Journal of Hematology 2021 被引用: 198

  20. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

    著者: Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, Emma Scott, Ahmad Halwani, Martin Gutierrez, Michael Millenson, Adam D. Cohen, Stephen J. Schuster, Daniel Lebovic, Madhav V. Dhodapkar, David Avigan, Bjoern Chapuy, Azra H. Ligon, Gordon J. Freeman, Scott J. Rodig, Deepika Cattry, Lili Zhu, Joseph F. Grosso, M. Brigid Garelik, Margaret A. Shipp, Ivan Borrello, John M. Timmerman - Journal of Clinical Oncology 2016 被引用: 1,011

  21. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

    著者: Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian T. Hill, Christina Howlett, Alan P Skarbnik, Bruce D. Cheson, Clive S. Zent, Jeffrey J. Pu, Pavel Kiselev, André Goy, David F. Claxton, Krista M. Isaac, Kaitlin Kennard, Colleen Timlin, Daniel J. Landsburg, Allison Winter, Sunita D. Nasta, Spencer Henick Bachow, Stephen J. Schuster, Colleen Dorsey, Jakub Svoboda, Paul M. Barr, Chaitra S. Ujjani - Haematologica 2018 被引用: 452

  22. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer

    著者: Yong Gu Lee, Puneeth Guruprasad, Guido Ghilardi, Raymone Pajarillo, C Sauter, Ruchi P. Patel, Hatcher J. Ballard, Seok Jae Hong, Inkook Chun, Nicholas Yang, Kimberly V. Amelsberg, Katherine D. Cummins, Jakub Svoboda, Saar Gill, Elise A. Chong, Khrystyna North, S. Church, Joseph A. Fraietta, Wan-Jung Chang, Simon F. Lacey, Xueqing Maggie Lu, Yunlin Zhang, Kanupriya Whig, D. Schultz, Sara Cherry, James N. Gerson, Stephen J. Schuster, Patrizia Porazzi, Marco Ruella - Cancer Discovery 2022 被引用: 98

  23. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

    著者: Nancy L. Bartlett, Sarit Assouline, Pratyush Giri, Stephen J. Schuster, Chan Y. Cheah, Matthew J. Matasar, Gareth P. Gregory, Dok Hyun Yoon, Mazyar Shadman, Keith Fay, Sung‐Soo Yoon, Carlos Panizo, Ian W. Flinn, Anna Johnston, Francesc Bosch, Laurie H. Sehn, Michael C. Wei, Shen Yin, Iris To, Chi‐Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde - Blood Advances 2023 被引用: 93

  24. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas

    著者: Guido Ghilardi, Elise A. Chong, Jakub Svoboda, Philipp Wohlfarth, Sunita D. Nasta, Staci Williamson, J.D. Landsburg, James N. Gerson, Stefan K. Barta, Raymone Pajarillo, Jessie Myers, A.I. Chen, Levanto Schachter, Rebecca Yelton, Hatcher J. Ballard, Alexandria Hodges Dwinal, Shannon Gier, Danielle Victoriano, Erin L. Weber, Ellen Napier, Alfred L. Garfall, David L. Porter, Ulrich Jäger, Richard T. Maziarz, Marco Ruella, Stephen J. Schuster - Annals of Oncology 2022 被引用: 97